Darrick M. Mix

Partner

  • Darrick M. Mix
  • Phone: +1 215 979 1206

    Read Darrick M. Mix's blog Darrick M. Mix - LinkedIn Import to Address Book

  • Duane Morris LLP
    30 South 17th Street
    Philadelphia, PA 19103-4196
    USA

Darrick M. Mix is head of the firm's Capital Markets group and is a member of the firm's governing Partners Board. Mr. Mix practices corporate law with concentrations in the areas of securities law, mergers and acquisitions and corporate governance. He has experience representing public and private companies in connection with their capital-raising activities, including public offerings and private placements of equity and debt securities. Mr. Mix also advises companies with respect to SEC regulations, compliance issues and other corporate and securities law matters, such as public reporting, Sarbanes-Oxley compliance and communications with analysts and investors. He has substantial experience representing public and private companies in selling and acquiring businesses His clients span a variety of industries, including biotech, industrials, retail, financial services and REITs.

Mr. Mix has been ranked in Chambers USA for Corporate/M&A and Private Equity. Mr. Mix is a member of the Title 15/Business Associations Committee of the Pennsylvania Bar Association and brings to his clients a unique knowledge of Pennsylvania's corporation law.

Mr. Mix is a 1997 graduate, with honors, of the Ohio State University, Michael E. Moritz College of Law, and received a Bachelor of Science in Foreign Service Degree from Georgetown University's School of Foreign Service.

Representative Matters

  • Represented IQVIA Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, in connection with its acquisition of a life sciences consulting and communications company.

  • Representing Hill International, Inc. (NYSE: HIL), a leading provider of construction project management services, in its sale to Global Infrastructure Solutions Inc., in a transaction with an enterprise value of $350 million. 

  • Represented IQVIA Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, in connection with its acquisition of all shares of capital stock of Cronos Clinical Consulting Services Inc., a leading global provider of specialty clinical service solutions with the goal of improving data quality in clinical trials.

  • Represented DuPont (NYSE: DD) in the sale of its Solamet business, which manufactures solar cell paste to deliver higher solar energy efficiency, to a private equity-sponsored business in China.

  • Represented Diversey Holdings, Ltd. (Nasdaq: DSEY), a leading hygiene, infection preventing and cleaning solutions company, in connection with its acquisition of an Ohio-based developer, manufacturer and distributor of professional hygiene products and services, as well as a manufacturing facility.

  • Represented Firmenich Inc., one of the world's largest producers of flavors and fragrances, in connection with its minority investment in a strategic target with an option to acquire the remainder of the company.

  • Represented DuPont (NYSE: DD), a global innovation leader with technology-based materials, in its $110 million acquisition of Evoqua’s Memcor business, which includes ultrafiltration and membrane bio-filtration technologies.

  • Represented Firmenich, Inc. in its acquisition of Senomyx, Inc. (Nasdaq: SNMX), a developer of innovative flavor ingredients and natural high intensity sweeteners for the packaged food, beverage and ingredient supply industries.

  • Represented Mannington Mills, a leading manufacturer of fine flooring, in its acquisition of Phenix Flooring and Pharr Fibers and Yarns, a leader in the flooring industry and pioneer in the solution-dyed arena, from Pharr USA.

  • Represented certain investors in a $361 million investment into Covetrus, Inc., a spin out comprised of assets from Henry Schein, Inc. (a publicly traded company) and Vets First Choice (a private equity backed company), as part of a larger $1.5 billion transaction.

  • Represented Firmenich, Inc. in its acquisition of Natural Flavors, Inc., a producer of natural and organic flavor products.

  • Represented IQVIA Inc., a leading world-wide integrated information and technology-enabled healthcare service provider, in connection with the acquisition of 100 percent of the outstanding membership interests of Chemical Information Services, LLC, a private equity-backed-Dallas-based technology company that provides online databases for chemical and pharmaceutical companies.

  • Represented Firmenich, Inc. in connection with its acquisition of Agilex Holdings, Inc., a portfolio company of New York-based private equity firm MidOcean Partners.

  • Represented the special committee of the Board of Directors of JAVELIN Mortgage Investment Corp. (NYSE: JMI) in a merger agreement in which ARMOUR Residential REIT, Inc. (NYSE: ARR) will acquire JAVELIN, and its $900 million of assets, in a tender offer for cash consideration based on 87% of JAVELIN's book value per share.

  • Advised Hill International (NYSE:HIL), a Philadelphia-based project management company, in the sale of its Construction Claims Group to UK-based private equity firm Bridgepoint Development Capital for $147 million.

  • Advised Firmenich Inc. on US matters in connection with its agreement to acquire Les Dérivés Résiniques et Terpéniques (DRT), a world leader in plant-based chemistry, and a leading global supplier of renewable ingredients, from private equity owners Ardian Buyout and Tikehau Capital and family shareholders.

  • Represented SunPower (NASDAQ: SPWR), a solar energy company, in its $75 million strategic divestiture of its microinverter assets (including more than 140 patents) and SunPower’s long-term supply agreement with Enphase Energy (NASDAQ: ENPH).

  • Represented Voxx International Corporation in its acquisition of 54 percent of the assets of EyeLock, Inc., a Puerto Rico corporation, and EyeLock Corporation, a Delaware corporation, and a wholly-owned subsidiary of EyeLock, Inc.

  • Represented financial services and investment firm Cohen & Company Inc. (NYSE American: COHN), as issuer, in its $75 million at-the-market offering, with Northland Capital Markets as sales agent.

  • Represented Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing antiviral therapies to treat diseases associated with an abnormal immune response, such as fibromyalgia, in its initial public offering.

  • Represented Annovis Bio, Inc. (NYSE: ANVS), a pharmaceutical company focused on the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, in connection with its initial public offering.

  • Represented Annovis Bio, Inc. (NYSE: ANVS) in a $50 million underwritten offering of common stock.

  • Represented Immunome Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, in its $75 million at-the-market offering, with Jefferies LLC as sales agent.

  • Represented Hill International Inc., a global leader in managing construction risk, in a $165 million debt refinancing transaction.

  • Represented VEREIT, Inc. (NYSE: VER) a NYSE-traded REIT, in a merger transaction valued at $3.1 billion to acquire American Realty Capital Trust IV, Inc., a "non-traded" REIT. The combined company as a result of the merger had pro forma enterprise value of $10 billion.

  • Represented National Securities Corporation, as underwriter and sole book running manager, in connection with the initial public offering by CBD Energy Limited, a diversified clean energy company and leading provider of solar installations worldwide.

  • Represented VEREIT, Inc. (NYSE: VER) a NYSE-traded REIT, in a merger transaction valued at $3.2 billion to acquire American Realty Capital Trust III, Inc., a "non-traded" REIT. The combined company as a result of the merger had pro forma enterprise value of $10 billion.

  • Represented Lehigh Gas Partners LP, a wholesale motor fuel distributor now known as CrossAmerica Partners LLP, in connection with its $138 million IPO.

  • Represented a subsidiary of a French rail operator in a $12 million sale of its U.S. bus tour business.

  • Represented Iroko Pharmaceuticals, LLC in connection with a $140 million secured loan facility with CRG, a healthcare investment fund, and the simultaneous pay-off of Iroko's loan facility with another lender.

  • Represented a specialty chemical company, a portfolio company of a large private equity firm, in closing a $175 million credit facility, comprised of revolving credit, term loan, swing line and letters of credit sub-facilities. The credit agreement contained an accordion feature affording the client the right to increase the revolving credit facility size by $50 million. Also represented the company in its first “bolt-on” strategic acquisition with a transaction value of approximately $25 million.

  • Represented a Nasdaq-listed retail department store company in a $1 billion acquisition and the related offering of $600 million in debt securities.

Areas of Practice

  • Corporate Law
  • Securities Law
  • Mergers & Acquisitions

Admissions

  • Pennsylvania
  • Ohio

Education

  • Georgetown University, B.S.F.S., 1994
  • The Ohio State University, Michael E. Moritz College of Law, J.D., with honors, 1997

Professional Activities

  • American Bar Association

  • Pennsylvania Bar Association
    - Member of the Title 15/Business Associations Committee

  • Philadelphia Bar Association

Honors and Awards

  • Ranked in Chambers USA: America's Leading Lawyers for Business for Corporate/M&A & Private Equity

  • Rated as "Highly Regarded" for Capital Markets: Debt and Capital Markets:Equity by IFLR1000, 2018-2023

Selected Publications

Media Hits

Selected Speaking Engagements

  • Panelist, "Climate Governance and the Board's Role in Managing Strategic Risk," National Association of Corporate Directors, October 18, 2022
  • Speaker, "Best Practices for 10b5-1 Plans in 2021," Morgan Stanley Webinar, July 21, 2021
  • Speaker, "16th Annual International Estate Planning Institute," New York State Bar Association, Webinar, October 8, 2020
  • Panelist, "The Board’s Role in Mergers and Acquisitions,"  2019 Drexel University Gupta Governance Institute, Drexel Lebow School of Business, Philadelphia, October 30, 2019

  • Moderator, "Succession Planning: Talent, Strategy and Risk," Philadelphia Chapter of NACD (National Association of Corporate Directors), The Union League of Philadelphia, September 10, 2019

  • Panelist and Presenter, Federal Securities Law Forum, Pennsylvania Bar Institute, April 21, 2017
  • Panelist and Presenter, Federal Securities Law Forum, Pennsylvania Bar Institute, April 15, 2016
  • Panelist, "Crowdfunding for Life Sciences: A bridge over troubled waters?" Pharmaceutical Consulting Consortium, Inc., May 12, 2014
  • Panelist, "Crowdfunding and Rule 506(c): Brave New Capital-Raising World," Pennsylvania Business Brokers Association, April 2, 2014
  • Presenter, "Crowdfunding under the JOBS Act," Pennsylvania Bar Association, July 23, 2013